Table 2.
Regression output on the association of higher medication adherence with hospitalized exacerbations.
| Variable | Abbreviation | Estimate coefficient | Std. error | OR | 95% CI | Significance marker |
|---|---|---|---|---|---|---|
| Category 2 of the proportion of days with medication reserve | Q2 | −0.319 | 0.074 | 0.73 | (0.63–0.84) | *** |
| Category 3 of the proportion of days with medication reserve | Q3 | −0.479 | 0.085 | 0.62 | (0.52–0.73) | *** |
| Category 4 of the proportion of days with medication reserve | Q4 | −0.637 | 0.100 | 0.53 | (0.43–0.65) | *** |
| Category 5 of the proportion of days with medication reserve | Q5 | −0.709 | 0.089 | 0.49 | (0.41–0.59) | *** |
| Current deductible = 500 | F500 | −0.018 | 0.065 | 0.98 | (0.86–1.12) | – |
| Current deductible = 1000 | F1000 | −0.115 | 0.186 | 0.89 | (0.61–1.29) | – |
| Current deductible = 1500 | F1500 | 0.238 | 0.140 | 1.27 | (0.96–1.68) | – |
| Current deductible = 2000 | F2000 | 0.024 | 0.371 | 1.02 | (0.49–2.15) | – |
| Current deductible = 2500 | F2500 | −0.043 | 0.236 | 0.96 | (0.60–1.54) | – |
| Premium reduction | R | 0.261 | 0.057 | 1.30 | (1.16–1.45) | *** |
| Age | A | 0.017 | 0.002 | 1.02 | (1.01–1.02) | *** |
| Increase of the franchise | F+ | −0.138 | 0.237 | 0.87 | (0.54–1.40) | – |
| Reduction of the franchise | F- | −0.181 | 0.138 | 0.83 | (0.63–1.10) | – |
| Hospitalized exacerbation during the observation period | Et-2 | 1.580 | 0.087 | 4.85 | (4.08–5.78) | *** |
| Prescription of short-acting medication | B | 1.280 | 0.058 | 3.60 | (3.20–4.04) | *** |
| Methylxanthine prescription | M | 0.510 | 0.476 | 1.67 | (0.64–4.31) | – |
| Prescription of phosphodiesterase 4 inhibitors. | P | 1.410 | 0.194 | 4.10 | (2.78–6.04) | *** |
| Prescription of mucolytic | K | −0.186 | 0.100 | 0.83 | (0.68–1.01) | – |
| Intercept | 31.600 | 5.020 | – | (0.63–0.84) | *** |
The significance levels were set at *p < 0.1, **p < 0.05, and ***p < 0.01; OR = Odds ratio; CI = Confidence Interval
OR odds ratio; CI confidence interval